Amneal Pharmaceuticals (AMRX) Interest & Investment Income (2017 - 2026)

Amneal Pharmaceuticals' Interest & Investment Income history runs 10 years deep, the most recent figure standing at -$53.4 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 6.28% year-over-year to -$53.4 million; the TTM figure through Mar 2026 stood at -$237.5 million (up 4.93% YoY), while the FY2025 annual figure was -$241.1 million, up 6.77% from the prior year.
• Interest & Investment Income was -$53.4 million for Q1 2026 at Amneal Pharmaceuticals, up from -$56.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of -$33.3 million in Q1 2022 to a low of -$65.7 million in Q2 2024.
• Historically, Interest & Investment Income has averaged -$54.2 million across 5 years, with a median of -$56.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income slumped 47.94% in 2023, then increased 13.34% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at -$47.0 million in 2022, then declined by 26.62% to -$59.5 million in 2023, then retreated by 3.55% to -$61.7 million in 2024, then advanced by 8.8% to -$56.2 million in 2025, then grew by 5.11% to -$53.4 million in 2026.
• The last three Interest & Investment Income figures came in at -$53.4 million (Q1 2026), -$56.2 million (Q4 2025), and -$62.8 million (Q3 2025), per Business Quant data.